Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775982 | 0.88 | CACNA1G (0.43) | RPS6KA3RPS6KA2PRKDCATR | |
| SCHEMBL16775983 | 0.86 | HDAC2 (0.39) | RPS6KA2MLNROPRM1OPRD1MTOR | |
| SCHEMBL16775990 | 0.85 | ADORA2A (0.39) | MLNRMTORLRRK2ADORA2A | |
| SCHEMBL16775991 | 0.84 | THRB (0.39) | MLNRMTORLRRK2ADORA2AATR | |
| SCHEMBL16775933 | 0.84 | USP30 (0.39) | MLNRMTORLRRK2ADORA2A | |
| SCHEMBL16775979 | 0.83 | CREBBP (0.44) | OPRM1OPRD1MTORLRRK2ATR | |
| SCHEMBL19670593 | 0.83 | JAK1 (0.38) | RPS6KA2MLNRMETSCDJAK1 | |
| SCHEMBL16775942 | 0.83 | HDAC2 (0.37) | MLNRMTORADORA2A | |
| SCHEMBL16775980 | 0.82 | GRM5 (0.39) | MLNRMTORLRRK2ADORA2A | |
| SCHEMBL16775978 | 0.82 | MLNR (0.38) | MLNRMTORLRRK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RPS6KA3 2368/4885RPS6KA2 2318/4885MLNR 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.